In cancer care, health literacy doesn’t just shape understanding—it shapes experience. A population study (PROFILES registry) found that even among high–health literacy patients, those with rare cancers reported lower satisfaction, information access, and quality of life than

In clinical genetics, words are interventions. This paper argues for precise, empathetic language—using terms like “variant” instead of “mutation,” and avoiding binary labels like “positive” or “negative.” As genetic testing becomes routine in oncology, communication must

The NSABP B-51/RTOG 1304 trial just rewrote part of the breast cancer playbook. For patients who clear nodes after neoadjuvant chemo, regional nodal irradiation adds no survival benefit—marking a clear shift toward de-escalation without compromise. Beyond practice change, it

As a medical profession we need to take posts like this one seriously It is a big problem (and undermines any hope of therapeutic alliance) if our patients don’t feel heard In fact I would argue that our jobs, both diagnostically and therapeutically, are easier when we listen

Despite longer survival in multiple myeloma, bone disease remains a relentless source of pain and fractures for patients. This review underscores the vital role of bisphosphonates and emerging bone-targeting strategies—highlighting how we can better personalize care to protect

Risk stratification in NSCLC remains a hurdle—how can we better pinpoint patients at high risk beyond traditional staging? This study leverages AI-powered spatial cellomics to dissect 43 distinct cell phenotypes within the tumor microenvironment of over 1100 patients,

The Oncotype DX test has transformed breast cancer treatment decisions—reducing both over- and undertreatment. Yet across Europe, implementation lags. This review breaks it down: • IVDR raises regulatory demands • HTA & reimbursement vary by country • Real-world data remain

The gut microbiome continues to prove it’s not just a bystander in immuno-oncology. A meta-analysis of 38 studies (5,642 pts) found enrichment of Akkermansia, Bifidobacterium, and Faecalibacterium linked to better OS and PFS with immune checkpoint inhibitors. Antibiotic use

🚨 FDA Approval Alert: this 🧵 represent my opinion: On Nov 6, 2025, the FDA approved daratumumab high-risk smoldering multiple myeloma (SMM). 🧬 First therapy approved for this stage of disease based on AQUILA study #Myeloma #FDA 1/I agree with treating patients with

👏 Dara an option for 🇺🇸 pts with HR-SMM. Seems that USPI will leave definition to us; great since allows for genomic & longitudinal risk assessments. Shared decision-making with patients will be key. Almost exactly 10 years to the day since dara's first approval in #MMsm!

In managing advanced breast cancer, does integrating palliative care early alongside oncological treatment truly shift outcomes? This RCT reveals not just improved symptom control and quality of life, but hints at a survival benefit—without sacrificing aggressive tumor-directed

Cutting nicotine—not just cutting smoking—may be the most impactful cancer prevention move we can make. Trials show that lowering nicotine content in cigarettes by ~95% reduces exposure, cuts consumption, and boosts quit rates. Modeling suggests an FDA nicotine cap of 0.7 mg/g

Ozempic and Zepbound are just the beginning of the expanded medical GI hormone era. A new selective amylin mimetic (pancreatic peptide)) achieved marked weight loss and reduced inflammation without a plateau effect in a randomized trial @TheLancet https://t.co/c3lINkhtcu

Safe venous access is foundational but fraught with complication risks in cancer care. The new MAGIC-ONC guidance, developed via rigorous RAND/UCLA methodology and 1,422 detailed clinical scenarios, refines how to choose and manage vascular access devices by cancer type, urgency,

In metastatic castration-resistant prostate cancer treated with [Lu]Lu-PSMA-617, traditional markers like PSA and baseline PET can miss key prognostic signals. This study highlights how fast, whole-body 360° [Lu]Lu SPECT with a CZT camera detects new bone lesions during therapy

For patients navigating cancer's exhausting journey, this study highlights that sustaining 150 minutes of weekly physical activity during active treatment can meaningfully ease fatigue and uplift quality of life across many domains. Source:

Longitudinal real-world data from Scotland now confirms the bivalent HPV vaccine’s durable protection against CIN2+ and CIN3+ lesions up to 12 years post-vaccination—but only with complete dosing before age 18. Completing the 3-dose (or 2-dose, 5-month apart) bivalent HPV

The 2024 JSCCR guidelines for colorectal cancer embody a significant step toward truly patient-centered care in Japan, and they offer a valuable model for clinicians globally. By targeting key clinical controversies with evidence-grade recommendations, they offer a practical

💡 Adjuvant immunotherapy after surgery in esophageal cancer. Up to half of patients relapse after standard neoadjuvant chemotherapy or chemoradiotherapy (CRT) followed by surgery. In a single-center study (n = 690), immunotherapy and immunochemotherapy (ICT) significantly

Big day for a rare disease 🎉🧬 The new NCCN Guidelines for Appendiceal Cancer just dropped — and they’re fantastic. For the first time, this rare and often misunderstood disease finally gets its own dedicated guidance, instead of the old “just follow colorectal cancer”